At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
hCG +1 moredrug
Likely dose
hCG 1,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS
In Brief
A Phase 4 clinical trial evaluating hCG for Ovarian Hyperstimulation Syndrome. Completed, enrolled 89 participants across 1 site.
Detailed Summary
This a prospective randomized double blind study involving patients at high risk of OHSS development with peak serum E2 levels \< 4,000 pg/ml comparing the ongoing pregnancy rates in patients who receive adjuvant hCG 1,000 IU at the time of GnRH agonist trigger or adjuvant hCG 1,500 IU 35 hours after GnRH agonist trigger.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Hyperstimulation Syndrome
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionDec 2015
Study CompletionOct 2016
TodayJul 2026
First PostedMar 20, 2013
Enrollment StartMar 1, 2013
Primary CompletionDec 1, 2015
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.3 years ago
Interventions
hCGdrug
Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
hCGdrug
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger